Extended indication Chlamydial infections and Gonorrhoea (Prevention)
Therapeutic value Possibly no place in the treatment regimen
Registration phase Clinical trials

Product

Active substance Citric acid / lactic acid / potassium bitartrate
Domain Infectious diseases
Reason of inclusion Indication extension IND
Main indication Bacterial infections
Extended indication Chlamydial infections and Gonorrhoea (Prevention)
Proprietary name Phexxi
Manufacturer Evofem Biosciences
Mechanism of action Other
Route of administration Vaginal
Therapeutical formulation Gel
Budgetting framework Extramural (GVS)
Additional remarks Al geregistreerd in de Verenigde Staten als voorbehoedsmiddel.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date 2023
Expected Registration 2024
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value Possibly no place in the treatment regimen

This assessment does not indicate any potential inclusion in the package.

Dosage per administration 5g
References NCT03107377
Additional remarks 5g vaginaal aanbrengen ongeveer een uur voor de geslachtsgemeenschap

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Additional remarks De verwachting is dat het gebruik erg laag of er niet zal zijn. De voorkeur van arts en patiënt gaat waarschijnlijk naar een tabletvorm uit.

Expected cost per patient per year

Cost < 250.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References drugs.com
Additional remarks De kosten voor Phexxi vaginale gel (1%-1.8%-0.4%) is rond de $289 voor een hoeveelheid van 60 gram in de VS.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions No
References Adis Insight
Additional remarks Geen andere indicaties op dit moment onderzocht in fase 2 of 3.

Other information